Scientists Discover Potential Treatment Approaches for Polycystic Kidney Disease
April 4, 2024 -- Researchers have shown that dangerous cysts, which form over time in polycystic kidney disease (PKD), can be prevented by a single normal copy of a defective gene. This means the potential exists that scientists could one day tailor... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 4, 2024 Category: Pharmaceuticals Source Type: clinical trials
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients With Platinum-Resistant Ovarian Cancer
BASKING RIDGE, N.J.& RAHWAY, N.J., April 3, 2024– Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the first patient has been dosed in... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 3, 2024 Category: Pharmaceuticals Source Type: clinical trials
Drug Shows Promise for Slowing Progression of Rare, Painful Genetic Disease
April 3, 2024 -- A drug used to treat certain bone diseases shows promise for slowing the progression of a rare, painful genetic condition that causes excessive calcium buildup in the arteries, known as arterial calcification due to deficiency of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 3, 2024 Category: Pharmaceuticals Source Type: clinical trials
LENZ Therapeutics Announces Positive Topline Data from Aceclidine Phase 3 CLARITY Presbyopia Trials
SAN DIEGO--(BUSINESS WIRE) April 03, 2024 -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or“LENZ” or the“Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 3, 2024 Category: Pharmaceuticals Source Type: clinical trials
First Patient Dosed in Phase 2a Clinical Trial of a First-in-Class Regenerative Cell Therapy for Patients with End-Stage Liver Disease
PITTSBURGH, April 2, 2024. LyGenesis, a clinical-stage biotechnology company developing cell therapies for large unmet medical needs, announced today that the first patient has been dosed in their Phase 2a clinical trial... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 2, 2024 Category: Pharmaceuticals Source Type: clinical trials
Positive Recommendation to Continue Phase 3 Clinical Trial of Leuprolide Injectable Emulsion for the Treatment of Central Precocious Puberty
TAIPEI, April 1, 2024 -- Foresee Pharmaceuticals ( " Foresee " ) today announces the positive safety review by the independent Data and Safety Monitoring Board for its Casppian Phase 3 registration study. The DSMB recommended that Foresee... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 2, 2024 Category: Pharmaceuticals Source Type: clinical trials
Priovant Therapeutics Announces Positive Phase 2 NEPTUNE Study Results for Brepocitinib in Non-Infectious Uveitis (NIU), Showing Strongest Efficacy Data in NIU Observed to Date
DURHAM, N.C., April 2, 2024 /PRNewswire/ -- Priovant Therapeutics today announced positive results from the Phase 2 study (NEPTUNE) evaluating brepocitinib in non-anterior non-infectious uveitis.
The NEPTUNE study enrolled 26 subjects with active... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 2, 2024 Category: Pharmaceuticals Source Type: clinical trials
Otsuka and Click Therapeutics Announce the U.S. Food and Drug Administration (FDA) Clearance of Rejoyn, the First Prescription Digital Therapeutic Authorized for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms
PRINCETON, N.J. and NEW YORK, N.Y. (April 1, 2024)– Otsuka Pharmaceutical, Co. Ltd. (Otsuka) and Click Therapeutics, Inc., (Click) announce that the U.S. Food and Drug Administration (FDA) has cleared Rejoyn™ (developed as CT-152), the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 1, 2024 Category: Pharmaceuticals Source Type: clinical trials
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced the initiation of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 1, 2024 Category: Pharmaceuticals Source Type: clinical trials
Positive Interim Phase I Results of Zolmitriptan Transdermal Microporation System for the Treatment of Acute Migraine
SAN DIEGO, March 29, 2024. PassPort Technologies, Inc. (PPTI), based in San Diego, a clinical-stage drug and medical device development company, today announced positive interim results from the Phase 1 (Part A) clinical trial of Zolmitriptan... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 29, 2024 Category: Pharmaceuticals Source Type: clinical trials
Johnson & Johnson's Nipocalimab Granted U.S. FDA Fast Track Designation to Reduce the Risk of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT) in Alloimmunized Pregnant Adults
SPRING HOUSE, Pa. March 26, 2024– Johnson& Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) for nipocalimab to reduce the risk of FNAIT in alloimmunizeda pregnant adults... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 26, 2024 Category: Pharmaceuticals Source Type: clinical trials
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome
CHATHAM, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the U.S. Food... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 25, 2024 Category: Pharmaceuticals Source Type: clinical trials
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that AXS-12... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 25, 2024 Category: Pharmaceuticals Source Type: clinical trials
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced topline... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 25, 2024 Category: Pharmaceuticals Source Type: clinical trials
